Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial

G. Robert,Aurélien Descazeaud,G. Karsenty,C. Saussine,Abdel-Rahmène Azzouzi,Alexandre de la Taille,F. Desgrandchamps,Antoine Faix,Marc Fourmarier,Aurore Georget,Antoine Bénard,Nicolas Barry Delongchamps

Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial

2018

G. Robert
Aurélien Descazeaud
G. Karsenty
C. Saussine
Abdel-Rahmène Azzouzi
Alexandre de la Taille
F. Desgrandchamps
Antoine Faix
Marc Fourmarier
Aurore Georget
Antoine Bénard
Nicolas Barry Delongchamps

Objective To explore efficacy and safety of Botulinum Neurotoxin Type A (BoNT-A) prostatic injection in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperperplasia.

Keywords:

Urology
Randomized controlled trial
Botulinum Neurotoxin Type A
Botulinum toxin
Prostate
Hyperplasia
Medicine
Lower urinary tract symptoms
medical therapy
Internal medicine
Placebo
Nephrology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations